The Cigna Group (CI)
NYSE · Bloomfield, Connecticut, USA · Founded 1982 · CEO Brian Evanko
Valuation summary
$707.72 fair value versus $273.04 in the market, a difference of +159.2%. Rated Strong Buy.
| Fair value per share | $707.72 |
| Current share price | $273.04 |
| Upside / downside | +159.2% |
| Bear case | $191.79 |
| Bull case | $1,557.16 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.60% |
| Market capitalisation | $72B |
| EV / Sales | 0.3x |
About The Cigna Group
Formed in 1982 by the merger of Connecticut General and INA, with roots back to 1792. Brian Evanko succeeded David Cordani, chief executive since 2009, as CEO in July 2026, with Cordani becoming executive chair. The Cigna Group has two very different businesses: Evernorth, which contains Express Scripts, one of the three pharmacy benefit managers that negotiate drug prices for most Americans, and Cigna Healthcare, a commercial health insurer. Evernorth generates most of the profit and is where the political risk sits.
Investment case
- Express Scripts is one of three pharmacy benefit managers controlling the vast majority of US prescription volume.
- Exited Medicare Advantage, avoiding the utilisation problems that have hurt peers.
- Specialty pharmacy is a large and structurally growing profit pool.
Key risks
- Pharmacy benefit managers face intense bipartisan political scrutiny over drug pricing and rebate practices.
- PBM reform passed in February 2026 delinks PBM pay from drug prices in Medicare Part D and requires full rebate pass-through for commercial plans, mostly from 2028 or 2029.
- Commercial insurance is exposed to employment levels and medical cost trends.
Recent developments
- 2026-09-30 · Investor day reaffirmed 2026 adjusted EPS of at least $30.45, set a 10-14% annual EPS growth target to 2030 and a $3 bn productivity programme. source
- 2026-09-04 · PBM reform in the Consolidated Appropriations Act 2026 delinks Part D PBM pay and mandates commercial rebate pass-through, mostly from 2028-29. source
Revenue by segment
| Evernorth Health Services | 78% |
| Cigna Healthcare | 22% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $307.4B | $8.6B |
| Year 2 | $328.3B | $9.7B |
| Year 3 | $350.7B | $11.0B |
| Year 4 | $374.5B | $12.5B |
| Year 5 | $400.0B | $14.0B |
What the street says
Cheap relative to peers, with the discount reflecting political risk to the PBM model rather than operational problems. At its September 2026 investor day the new management team reaffirmed 2026 adjusted EPS of at least $30.45 and set a 10-14% annual EPS growth target through 2030, but the shares fell about 3% because the outlook was not raised.
Comparable companies: CVS · ELV · COR · MDLN · HCA · CAH · IQV · GEHC
Open the interactive model, price chart and sensitivity grid →